AZD-5904 is under clinical development by Conduit Pharmaceuticals and currently in Phase I for Male Infertility. According to GlobalData, Phase I drugs for Male Infertility does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the AZD-5904 LoA Report. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AZD-5904 overview

AZD5904 is under development for the treatment of idiopathic male infertility and glioma. The drug candidate acts by myeloperoxidase (MPO). It is administered through oral route as solution.

It was also under development for multiple sclerosis (MS) and COPD.

Conduit Pharmaceuticals overview

Conduit Pharmaceuticals is a biopharmaceutical company that is involved in developing AZD5904 (myeloperoxidase inhibitor) and AZD1656 (glucokinase activator) for the treatment of idiopathic male infertility and autoimmune diseases or immunodeficient conditions such as uveitis, preterm labor, renal transplant rejection and Hashimoto’s Thyroiditis. It is headquartered in San Diego, California, the US.

For a complete picture of AZD-5904’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.